{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:37:42Z","timestamp":1792197462294,"version":"4.4.0"},"reference-count":109,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.4065\/mcp.2011.0247","type":"journal-article","created":{"date-parts":[[2011,7,29]],"date-time":"2011-07-29T13:35:25Z","timestamp":1311946525000},"page":"805-817","source":"Crossref","is-referenced-by-count":333,"title":["Current Concepts in Antifungal Pharmacology"],"prefix":"10.4065","volume":"86","author":[{"given":"Russell E.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.4065\/mcp.2011.0247_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1378\/chest.54.Supplement_1.296","article-title":"The discovery and development of amphotericin B","volume":"54","author":"Dutcher","year":"1968","journal-title":"Dis Chest"},{"issue":"20","key":"10.4065\/mcp.2011.0247_bib2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N Engl J Med"},{"issue":"9312","key":"10.4065\/mcp.2011.0247_bib3","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(02)08162-X","article-title":"Antifungal drug resistance of pathogenic fungi","volume":"359","author":"Kontoyiannis","year":"2002","journal-title":"Lancet"},{"issue":"7","key":"10.4065\/mcp.2011.0247_bib4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.2042-7158.1992.tb05478.x","article-title":"The pharmacokinetics of oral itraconazole in AIDS patients","volume":"44","author":"Smith","year":"1992","journal-title":"J Pharm Pharmacol"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib5","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0247_bib6","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/jac\/dki220","article-title":"Making sense of itraconazole pharmacokinetics","volume":"56","author":"Prentice","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib8","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1086\/374557","article-title":"Voriconazole treatment for less-common, emerging, or refractory fungal infections","volume":"36","author":"Perfect","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nrd2270","article-title":"Posaconazole","volume":"6","author":"Kauffman","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1345\/aph.1L005","article-title":"Posaconazole: an oral triazole with an extended spectrum of activity","volume":"42","author":"Rachwalski","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"24","key":"10.4065\/mcp.2011.0247_bib11","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/13543780903176407","article-title":"New generation azole antifungals in clinical investigation","volume":"18","author":"Girmenia","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"25","key":"10.4065\/mcp.2011.0247_bib15","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N Engl J Med"},{"issue":"24","key":"10.4065\/mcp.2011.0247_bib16","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.4065\/mcp.2011.0247_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.4065\/mcp.2011.0247_bib18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1086\/423381","article-title":"Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy","volume":"39","author":"Maertens","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib20","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0966-842X(03)00117-3","article-title":"Antifungal agents: mechanisms of action","volume":"11","author":"Odds","year":"2003","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/AAC.47.2.577-581.2003","article-title":"Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome p450 14 alpha-demethylase","volume":"47","author":"Mann","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.4065\/mcp.2011.0247_bib22","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1128\/AAC.48.7.2747-2750.2004","article-title":"Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs","volume":"48","author":"Mellado","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1128\/JCM.01915-07","article-title":"Candida krusei, a multidrugresistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib24","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/JCM.00946-09","article-title":"Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007","volume":"47","author":"Pfaller","year":"2009","journal-title":"J Clin Microbiol"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00002018-199818020-00001","article-title":"Systemic antifungal agents: drug interactions of clinical significance","volume":"18","author":"Albengres","year":"1998","journal-title":"Drug Saf"},{"issue":"suppl 2","key":"10.4065\/mcp.2011.0247_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1439-0507.1999.tb00026.x","article-title":"Activity of terbinafine against serious fungal pathogens","volume":"42","author":"Ryder","year":"1999","journal-title":"Mycoses"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1128\/AAC.34.2.183","article-title":"Amphotericin B: current understanding of mechanisms of action","volume":"34","author":"Brajtburg","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0247_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1054-3589(08)60129-5","article-title":"Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development","volume":"44","author":"Groll","year":"1998","journal-title":"Adv Pharmacol"},{"issue":"5","key":"10.4065\/mcp.2011.0247_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1592\/phco.23.5.572.32209","article-title":"Variability in polyene content and cellular toxicity among deoxycholate amphotericin B formulations","volume":"23","author":"Cleary","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib30","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/314495","article-title":"Amphotericin B activation of human genes encoding for cytokines","volume":"178","author":"Rogers","year":"1998","journal-title":"J Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib32","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.drup.2006.01.001","article-title":"Update on antifungal drug resistance mechanisms of Aspergillus fumigatus","volume":"8","author":"Chamilos","year":"2005","journal-title":"Drug Resist Updat"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib33","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.01280-07","article-title":"Potential basis for amphotericin B resistance in Aspergillus terreus","volume":"52","author":"Blum","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.4065\/mcp.2011.0247_bib34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1056\/NEJMct060052","article-title":"Echinocandins for candidemia in adults without neutropenia","volume":"355","author":"Bennett","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"10.4065\/mcp.2011.0247_bib35","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.41.11.2471","article-title":"Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors","volume":"41","author":"Douglas","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"9390","key":"10.4065\/mcp.2011.0247_bib36","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.4065\/mcp.2011.0247_bib38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0006-2952(78)90507-5","article-title":"Mode of action of 5-fluorocytosine","volume":"27","author":"Diasio","year":"1978","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib39","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/clind\/15.6.1003","article-title":"Evolving role of flucytosine in immunocompromised patients \u2013 new insights into safety, pharmacokinetics, and antifungal therapy","volume":"15","author":"Francis","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0247_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2125.2003.01991.x","article-title":"The pharmacokinetics of voriconazole","volume":"56","author":"Johnston","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.4065\/mcp.2011.0247_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1592\/phco.19.8.603.31529","article-title":"Itraconazole in cyclodextrin solution","volume":"19","author":"Stevens","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib42","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.01034-08","article-title":"Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers","volume":"53","author":"Krishna","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1086\/597110","article-title":"Omeprazole significantly reduces posaconazole serum trough level [letter]","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.4065\/mcp.2011.0247_bib46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.4065\/mcp.2011.0247_bib47","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","article-title":"Clinical significance of the cytochrome P450 2C19 genetic polymorphism","volume":"41","author":"Desta","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/648679","article-title":"Voriconazole pharmacokinetics and pharmacodynamics in children","volume":"50","author":"Neely","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib49","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1128\/AAC.00896-10","article-title":"Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib50","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/clinids\/14.1.165","article-title":"Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations","volume":"14","author":"Tucker","year":"1992","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0247_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1365-2125.2003.01997.x","article-title":"Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration","volume":"56","author":"Purkins","year":"2003","journal-title":"Brit J Clin Pharmacol"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib53","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1128\/AAC.00579-07","article-title":"Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications","volume":"51","author":"Geist","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib54","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/650740","article-title":"Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations","volume":"50","author":"Hohmann","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"suppl","key":"10.4065\/mcp.2011.0247_bib55","doi-asserted-by":"crossref","first-page":"S349","DOI":"10.1080\/13693780600835724","article-title":"Managing drug interactions in the patient with aspergillosis","volume":"44","author":"Lewis","year":"2006","journal-title":"Med Mycol"},{"key":"10.4065\/mcp.2011.0247_bib56","series-title":"Drug Interactions in Infectious Diseases","first-page":"289","article-title":"Antifungal agents","author":"Gubbins","year":"2005"},{"issue":"suppl 1","key":"10.4065\/mcp.2011.0247_bib57","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds-Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.4065\/mcp.2011.0247_bib58","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1592\/phco.30.8.842","article-title":"Management of drug and food interactions with azole antifungal agents in transplant recipients","volume":"30","author":"Dodds-Ashley","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.4065\/mcp.2011.0247_bib59","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","article-title":"Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants","volume":"26","author":"Saad","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib60","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2165\/00023210-200721040-00004","article-title":"Fungal infections of the CNS: treatment strategies for the immunocompromised patient","volume":"21","author":"Black","year":"2007","journal-title":"CNS Drugs"},{"issue":"5","key":"10.4065\/mcp.2011.0247_bib61","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1586\/14787210.3.5.775","article-title":"Fungal CNS infections in patients with hematologic malignancy","volume":"3","author":"Pagano","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"8","key":"10.4065\/mcp.2011.0247_bib62","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1182\/blood-2005-02-0733","article-title":"Improved outcome in central nervous system aspergillosis, using voriconazole treatment","volume":"106","author":"Schwartz","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib63","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1128\/AAC.48.10.4063-4066.2004","article-title":"Efficacy of posaconazole in a murine model of central nervous system aspergillosis","volume":"48","author":"Imai","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib65","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.44.4.938-942.2000","article-title":"In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model","volume":"44","author":"Andes","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib66","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib67","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1128\/AAC.45.3.922-926.2001","article-title":"Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model","volume":"45","author":"Andes","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib68","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib69","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib70","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/AAC.50.3.935-942.2006","article-title":"Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases","volume":"50","author":"Hong","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib71","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib72","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In Vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.4065\/mcp.2011.0247_bib73","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity","volume":"49","author":"Louie","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.4065\/mcp.2011.0247_bib74","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1086\/424465","article-title":"Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity","volume":"190","author":"Wiederhold","year":"2004","journal-title":"J Infect Dis"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib75","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2011.01.004","article-title":"Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria","volume":"14","author":"Pfaller","year":"2011","journal-title":"Drug resist updat"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.idc.2006.06.007","article-title":"Pharmacokinetics and pharmacodynamics of antifungals","volume":"20","author":"Andes","year":"2006","journal-title":"Infect Dis Clin North Am"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib77","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1128\/AAC.00116-08","article-title":"Association of fluconazole pharmacodynamics with mortality in patients with candidemia","volume":"52","author":"Baddley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib78","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1128\/AAC.43.9.2116","article-title":"Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model","volume":"43","author":"Andes","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.4065\/mcp.2011.0247_bib80","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/infdis\/jir023","article-title":"Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy","volume":"203","author":"Howard","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1128\/AAC.00474-06","article-title":"Association of fluconazole area under the concentration-time curve\/MIC and dose\/MIC ratios with mortality in nonneutropenic patients with candidemia","volume":"51","author":"Pai","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.4065\/mcp.2011.0247_bib82","unstructured":"Clancy CJ, Kauffman CA, Morris A, et al. Correlation of fluconazole MIC and response to therapy for patients with candidemia due to C. albicans and non-C. albicans spp: results of a multicenter prospective study of candidemia. In: Proceedings of the 36th Annual Meeting of the Infectious Diseases Society of America. Denver, CO: 1998."},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib83","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0891-5520(03)00063-1","article-title":"Clinical pharmacodynamics of antifungals","volume":"17","author":"Andes","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib84","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drup.2010.09.002","article-title":"Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods","volume":"13","author":"Pfaller","year":"2010","journal-title":"Drug resist updat"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib85","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib86","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib87","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/QCO.0b013e3283184611","article-title":"Therapeutic drug monitoring for triazoles","volume":"21","author":"Hope","year":"2008","journal-title":"Curr Opin Infect Dis"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib88","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccm.2009.02.002","article-title":"Histoplasmosis","volume":"30","author":"Kauffman","year":"2009","journal-title":"Clin Chest Med"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib89","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/jac\/dkl550","article-title":"Flucytosine therapeutic monitoring: 15 years experience from the UK","volume":"59","author":"Pasqualotto","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.4065\/mcp.2011.0247_bib90","unstructured":"Glasmacher A, Hahn C, Molitor E, et al. Itraconazole for antifungal prophylaxis in neutropenic patients: a meat-analysis of 2181 patients. In: Proceedings of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago IL: 2001."},{"issue":"11\u201312","key":"10.4065\/mcp.2011.0247_bib91","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1439-0507.1999.00518.x","article-title":"Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules","volume":"42","author":"Glasmacher","year":"1999","journal-title":"Mycoses"},{"issue":"10","key":"10.4065\/mcp.2011.0247_bib92","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1001\/archinte.1989.00390100107024","article-title":"Itraconazole therapy for cryptococcal meningitis and cryptococcosis","volume":"149","author":"Denning","year":"1989","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib93","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0002-9343(89)90475-0","article-title":"Treatment of invasive aspergillosis with itraconazole","volume":"86","author":"Denning","year":"1989","journal-title":"Am J Med"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib94","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/jcp.50.6.477","article-title":"Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis","volume":"50","author":"Cartledge","year":"1997","journal-title":"J Clin Pathol"},{"issue":"6","key":"10.4065\/mcp.2011.0247_bib95","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1086\/605499","article-title":"Toxicodynamics of itraconazole: implications for therapeutic drug monitoring","volume":"49","author":"Lestner","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.4065\/mcp.2011.0247_bib96","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.4065\/mcp.2011.0247_bib97","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.bmt.1704828","article-title":"Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients","volume":"35","author":"Trifilio","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib98","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0091270005283837","article-title":"Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities","volume":"46","author":"Tan","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/mcp.2011.0247_bib99","series-title":"VFEND (voriconazole) Tablets, VFEND I.V., (voriconazole) VFEND (voriconazole) Oral Suspension [package insert]","year":"2004"},{"issue":"4","key":"10.4065\/mcp.2011.0247_bib100","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1128\/AAC.50.4.1570-1572.2006","article-title":"Voriconazole therapeutic drug monitoring","volume":"50","author":"Smith","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves safety and efficacy outcomes","volume":"46","author":"Pascual","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1128\/AAC.01027-09","article-title":"Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation","volume":"54","author":"Kohl","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.4065\/mcp.2011.0247_bib103","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib104","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1185\/03007990903485056","article-title":"Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"26","author":"AbuTarif","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.4065\/mcp.2011.0247_bib106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/clpt.2010.64","article-title":"Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma","volume":"88","author":"Jang","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"9270","key":"10.4065\/mcp.2011.0247_bib107","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","article-title":"Congestive heart failure associated with itraconazole","volume":"357","author":"Ahmad","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.4065\/mcp.2011.0247_bib108","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5070\/D352H3F976","article-title":"Voriconazole-associated phototoxicity [letter]","volume":"17","author":"Riahi","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.4065\/mcp.2011.0247_bib109","doi-asserted-by":"crossref","first-page":"351084","DOI":"10.1155\/2010\/351084","article-title":"Multifocal aggressive squamous cell carcinomas induced by prolonged voriconazole therapy: a case report","volume":"2010","author":"Morice","year":"2010","journal-title":"Case Report Med"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611651835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611651835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T23:32:32Z","timestamp":1638142352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611651835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":109,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0025619611651835"],"URL":"https:\/\/doi.org\/10.4065\/mcp.2011.0247","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}